These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 23831234)

  • 1. The promise and failures of epigenetic therapies for cancer treatment.
    Bojang P; Ramos KS
    Cancer Treat Rev; 2014 Feb; 40(1):153-69. PubMed ID: 23831234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
    Sahafnejad Z; Ramazi S; Allahverdi A
    Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation of gene expression as an anticancer drug target.
    Ferguson LR; Tatham AL; Lin Z; Denny WA
    Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epigenetic DNA and histone modifications to treat kidney disease.
    Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
    Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics in cancer: targeting chromatin modifications.
    Ellis L; Atadja PW; Johnstone RW
    Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the histone orthography of cancer: drugs for writers, erasers and readers.
    Simó-Riudalbas L; Esteller M
    Br J Pharmacol; 2015 Jun; 172(11):2716-32. PubMed ID: 25039449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Modulators as Therapeutic Agents in Cancer.
    Patnaik E; Madu C; Lu Y
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Organoselenium Compounds on Histone Deacetylase Inhibition and Their Potential for Cancer Therapy.
    Adimulam T; Arumugam T; Foolchand A; Ghazi T; Chuturgoon AA
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
    Katarzyna R; Lucyna B
    J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards the human cancer epigenome: a first draft of histone modifications.
    Fraga MF; Esteller M
    Cell Cycle; 2005 Oct; 4(10):1377-81. PubMed ID: 16205112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
    Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
    Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of the cancer epigenome.
    Mabe NW; Perry JA; Malone CF; Stegmaier K
    Nat Cancer; 2024 Jun; 5(6):844-865. PubMed ID: 38937652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.